November 1, 2016—Hospitals and health systems in the 340B drug discount program have asked the U.S. Justice Department to investigate whether drugmaker Mylan overcharged 340B healthcare providers for EpiPen anaphylaxis rescue auto-injectors.
You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register. Already registered? Click here to login. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)